nelarabine (CHEBI:63612)

ChEBI > Main

Main

ChEBI Ontology

Automatic Xrefs

Reactions

Pathways

Models

ChEBI Name	nelarabine

ChEBI ID	CHEBI:63612

Definition	A purine nucleoside in which O-methylguanine is attached to arabinofuranose via a β-N⁹-glycosidic bond. Inhibits DNA synthesis and causes cell death; a prodrug of 9-β-D-arabinofuranosylguanine (ara-G).

Stars	This entity has been manually annotated by the ChEBI Team.

Submitter	Anonymous

Supplier Information

Download	Molfile XML SDF

Formula

C11H15N5O5

Net Charge

Average Mass

297.26730

Monoisotopic Mass

297.10732

InChI

InChI=1S/C11H15N5O5/c1-20-9-5-8(14-11(12)15-9)16(3-13-5)10-7(19)6(18)4(2-17)21-10/h3-4,6-7,10,17-19H,2H2,1H3,(H2,12,14,15)/t4-,6-,7+,10-/m1/s1

InChIKey

IXOXBSCIXZEQEQ-UHTZMRCNSA-N

SMILES

COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O

Roles Classification
Biological Role(s):	DNA synthesis inhibitor Any substance that inhibits the synthesis of DNA.

Application(s):	antineoplastic agent A substance that inhibits or prevents the proliferation of neoplasms. prodrug A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.

ChEBI Ontology
Outgoing	nelarabine (CHEBI:63612) has functional parent 9-β-D-arabinofuranosylguanine (CHEBI:73141) nelarabine (CHEBI:63612) has functional parent guanine (CHEBI:16235) nelarabine (CHEBI:63612) has role antineoplastic agent (CHEBI:35610) nelarabine (CHEBI:63612) has role DNA synthesis inhibitor (CHEBI:59517) nelarabine (CHEBI:63612) has role prodrug (CHEBI:50266) nelarabine (CHEBI:63612) is a β-D-arabinoside (CHEBI:38315) nelarabine (CHEBI:63612) is a monosaccharide derivative (CHEBI:63367) nelarabine (CHEBI:63612) is a purine nucleoside (CHEBI:26394)

IUPAC Name

9-(β-D-arabinofuranosyl)-6-methoxy-9H-purin-2-amine

INN	Source
nelzarabine	KEGG DRUG

Synonyms	Sources
2-Amino-9-beta-D-arabinofuranosyl-6-methoxy-9H-purine	ChemIDplus
Nelzarabine	KEGG DRUG

Brand Name	Source
Arranon	DrugBank

Last Modified

22 February 2017